Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Taxus Express2: Pivotal trial data

Final 5-year follow-up data from 1,230 patients in the double-blind, U.S. TAXUS IV trial showed that all-cause

Read the full 170 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE